RESUMEN
OBJECTIVE: Few double-blind controlled trials have been reported on Chinese patent medicines for the treatment of chronic prostatitis. The purpose of this study was to investigate the therapeutic efficacy of Qianlie Jiedu Capsule for chronic prostatitis (CP) by the randomized double-blind controlled method. METHODS: Eighty CP patients were equally randomized into an experimental and a control group, the former treated with Qianlie Jiedu Capsule + Rufloxacin, and the latter given placebo + Rufloxacin, both for 4 weeks. All the patients were evaluated by NIH-CPSI and EPS examination before and after the medication. RESULTS: After 4-week treatment, the total score of NIH-CPSI and the scores of pain, voiding symptoms and quality of life were significantly decreased in both groups compared with the baseline (P < 0.05), so did the leukocyte count in EPS (P < 0.05). And the experimental group showed significant drops in the above scores as compared with the control (P < 0.05), except in the leukocyte count in EPS (P > 0.05). CONCLUSION: Qianlie Jiedu Capsule combined with Rufloxacin is highly effective for CP by relieving pain and voiding symptoms,decreasing the leukocyte count in EPS and improving the life quality of the patients.